British Journal of Clinical Pharmacology

Article	Citations
Issue Highlights	87
	71
Issue Information	61
	57
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	51
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food	51
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	50
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	47
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	46
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients	44
Letter to the editor of the Brit J Clin Pharmacol on Hartjes et al. 2025 https://doi.org/10.1002/bcp.70176	44
A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials	44
Impact of codeine rescheduling on prescribing of codeine and other opioids: Interrupted time series analyses using Australian general practice data	40
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	39
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	39
Neck‐vein thrombosis during spaceflight	38
Modelling the progression of illicit substance use patterns from real‐world evidence	38
Selected Abstracts from Pharmacology 2024	36
Lemborexant levels in breast milk after single doses in healthy, lactating women	36
Understanding the influence of transfusion and blood loss on tranexamic acid concentration in scoliosis surgery with blood loss	33
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients	33
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry	32
Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II	32
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia	31
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing	30

A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol	29
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity	29
Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase	29
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	29
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial	29
Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐	28
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	28
Prospective evaluation of pregnancy outcomes after gestational exposure to prazosin	28
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	27
Opioid‐related deaths and their counterpart by occurrence era, age group and coimplicated drugs: Scotland vs. England and Wales	26
Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens	26
Effects of intraoperative low‐dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double‐blind, placebo‐controlled study	26
Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model	26
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination	26
Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors	25
Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells	25
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	25
PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes	25
Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study	24
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	24
Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis	24
Issue Information	23
Longitudinal monitoring of cabotegravir and rilpivirine exposure from hair strand concentrations	22
Hospital pharmacists' opinions on a risk prediction tool for medication‐related harm in older people	22
Penicillin allergy de‐labelling in the critical care unit: Simulations to design an intravenous drug provocation test that mirrors the plasma profile of an enteral challenge	22
Predicting outcomes for spinal muscular atrophy: When the diagnosis no longer means what it used to mean	22
	21
Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023	21
Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant	21
Issue Highlights	21
Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients	20
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice	20
The trajectory of pharmacometrics to support drug licensing and labelling	19
From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy	19
Incorporating the One Health Philosophy into pharmacovigilance: Ecopharmacovigilance	19
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing	19
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria	19
Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self‐controlled case series study	19
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach	19
Cardiovascular and neuroendocrine dynamics in antibiotic dose individualization in intensive care	18
Unravelling sources of variability on rocuronium pharmacokinetics: Implications for prolonged recovery in older patients	18
Performance of the ChatGPT large language model for decision support in community pharmacy	18
Evaluating a virtual paediatric adverse drug reaction clinic	18
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach	18
Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations	18
Management of serotonin syndrome (toxicity)	18
Model‐informed precision dosing in paediatric intensive care: Bridging the gap between pharmacological optimization and clinical benefit	18
Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study	18
Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort study	18
A pharmacometrics model to define docetaxel target in early breast cancer	18

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach	18
Digital twins: Unlocking comparative evidence that clinical research urgently needs	17
The impact of a preprescribing formative assessment on learning in final‐year medical students using hospital inpatient electronic prescribing systems	17
Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care	17
From statistical inference to machine learning: A paradigm shift in contemporary cardiovascular pharmacotherapy	17
Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria	17
Spotlight commentary: Innovations in clinical trials	17
Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis	17
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite	17
Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women	17
Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients	17
	16
Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis	16
Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages	16
Population modelling of nilotinib exposure vs . longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimech	16
	16
Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update	16
Development of a nalmefene formulation suitable for a community‐use auto‐injector	16
Development and validation of a clinical risk score nomogram for predicting clozapine plasma concentrations below 350 ng/mL: A retrospective cohort study	16
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis	16
Optimization of vigabatrin dosage in children with epileptic spasms: A population pharmacokinetic approach	16
Assessing the feasibility of infusing slow normal saline through a three‐metre‐longline to maintain patency of a peripheral venous cannula: A pilot study	15
A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers	15
6‐Mercaptopurine metabolic profiles and clinical outcomes in TPMT and NUDT15 phenotypes during maintenance therapy for Thai paediatric acute lymphoblastic leukaemia	15
The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study	15
Issue Highlights	15
A single once daily ABC/DTG/3TC tablet predicts safe and effective exposures in children 3 to <6 kg	15
Cefuroxime axetil dosing regimens and probability of target attainment in adults and children	15
Issue Information	15
Association of state‐level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia	15
Issue Highlights	15
Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection	15
Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation	15
Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021	15
Hyperbaric oxygen should not be used routinely for carbon monoxide poisoning	15
Variability in the prevalence of inappropriate medication use among older adults: A review highlighting the importance of screening methods and database types	15
Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model	15
Cabotegravir PopPK analysis of adults and adolescents living with HIV/at risk for HIV receiving prep	15
Acute myocardial mechanical responses to colloid and crystalloid volume loading: A randomized double‐blind crossover study	14
Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report	14
Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants	14
Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis	14
Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients	14
Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties	14
Epigenetic modifications in drug‐induced liver injury: A systematic review	14
UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment	14
Assessment and evaluation of prescribing competences: A systematic review and recommendations	14
Precision therapy with quinidine of KCNT1‐related epileptic disorders: A systematic review	13
Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis	13
Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing	13
A crossover study evaluating the sex‐dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects	13
Results of the first international quality control programme for oral targeted oncolytics	13
Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis	13
Issue Information	13
A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU	13
Paediatric and obstetrical pharmacology – Pushing the frontier forward	13
Maternal exposure to folate antagonists and susceptibility to congenital heart disease in offspring: A systematic review and meta‐analysis	13
	13
Student perspectives on AI‐supported formative assessment in pharmacology	13
Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats	13
Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin‐I and blood concentration of cyclosporin A in real‐world patients	13
Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism	13
Issue Information	13
Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist	12
The cost‐effectiveness of cystic fibrosis transmembrane conductance regulator modulators: A systematic review of economic evaluations	12
A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis	12
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease	12
An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults	12
Identification and comparison of sex‐specific serious adverse drug reactions in spontaneous reports and systematically collected reports (ADRED)	12
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers	12
Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus	12
Issue Information	12
Correction to “Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006–2018): A nationwide register‐based study”	12
Appraising the visibility, relevance and impacts of clinical pharmacology	12
Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study	12
Infliximab‐induced symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) in a patient with ulcerative colitis	12
Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe	12
Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales	12
Association between use of lubiprostone and headache: A systematic review and meta‐analysis of randomized controlled trials	12
Application of immunocapture and nanoflow LC–MS/MS to overcome the barriers to the quantitation of oxytocin in plasma of women in third stage labour	12

Adherence levels and patterns for multiple cardiac medications prescribed to patients with incident atrial fibrillation events	12
Prescriptions of anti‐reflux drugs in neonatology and neonatal intensive care units: A large multicentre observational study (2014–2022)	12
Sustainable medicines development and use: Challenges and opportunities in the sustainable production of active pharmaceutical ingredients	12
Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4	12
Amoxicillin‐induced Erythema Scarlatiniforme Desquamativum Recidivans with cross‐reactivity to cefadroxil in a child: A case report and review of literature	11
Precision medicine in paediatrics: Progress and priorities	11
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study	11
Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies	11
Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV	11
Assessment of the influence of body fat indices on antihypertensive drug responses	11
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2	11
Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine	11
Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6	11
Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne	11
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation	11
Local variation in low carbon footprint inhalers in pre‐COVID pandemic primary care prescribing guidelines for adult asthma in England and its potential impact	11
Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients	11
Issue Information	11
A scoping review of quality prescribing indicators, rules and criteria for primary care	11
Trends in opioid prescribing in Scandinavian countries from 2010 to 2023: Insights from multi‐metric evaluation	11
Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration	11
Low‐dose amitriptyline: A potential therapeutic option for chronic pain in older people	11
Safe and supportive prescribing in transgender and non‐binary patients with cancer	11
Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy	11
Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin	11
Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome‐positive acute lymphoblastic leukaemia patients	11
	11
COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples	11
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus	11
Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis	11
External validation of a therapeutic window for risperidone in children with autism spectrum disorder	11
Mindfulness‐Oriented Recovery Enhancement: Implementing an evidence‐based intervention for chronic pain, opioid use, and opioid addiction in clinical settings	10
Clinical pharmacology in adolescent transgender medicine	10
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease	10
Issue Information	10
Pharmacokinetics of YK‐1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation	10
Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit	10
Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants	10
Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort	10
Population pharmacokinetics of rotigotine extended‐release microspheres for intramuscular injection in patients with early‐stage Parkinson's disease	10
Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants	10
Cannabidiol in autism: Clinical pharmacology priorities for trial design	10
Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial	10
Non‐compartmental and population pharmacokinetic analysis of dapsone in healthy NIGERIANS: A pilot study	10
Deprescribing anticholinergics—Why clinical significance matters more than p ‐values	10
	10
Prescribing variation across Europe: Insights into prescribing practices and educational needs	10
Developing an international concept‐based curriculum for pharmacology education: The promise of core concepts and concept inventories	10
Drug shortages. Part 1. Definitions and harms	10
Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam	10
Nonchemotherapy drug‐induced cytopenias: A cost‐of‐illness study using the microcosting methodology based on real‐world data	10
A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B	10
Potential drug–drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia	10
Successful treatment of hepatitis C virus infection in patients on anti‐epileptics or mood stabilizers using pharmacokinetic enhancers	10
Spotlight commentary: New Frontiers in pneumonia treatment	10
Understanding the impact of multimorbidity, medications and frailty on zoledronic acid efficacy in treating osteoporosis among older adults	9
Evaluation of cytochrome P450 (CYP) induction using RT‐qPCR in exosomes isolated from plasma samples: Method development and qualification	9
Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants	9
	9
Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction	9
Issue Highlights	9
Validating methods used to identify non‐adherence adverse drug events in Canadian administrative health data	9
Off‐label and unlicensed medicine prescribing in university hospital paediatric wards in Finland: A prospective study	9
Antiviral activity, safety and PK/PD of ACC017 in antiretroviral naïve HIV‐infected adults: A randomized, double‐blind, placebo/dose‐parallel‐controlled short‐term monotherapy study	9
Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus	9
Environmental impact of antidepressants: Is a new prescription framework possible?	9
Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions	9
A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system	9
Correction to “Minimizing prescribing errors: A phenomenological exploration of the views and experiences of independent prescribing pharmacists”	9
Population pharmacokinetic analysis of doravirine in real‐world people with HIV	9
Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients	9
Call to action: Harmonization of pharmacovigilance regulations for post‐marketing pregnancy and breastfeeding safety studies	9
Issue Highlights	9
Influence of age and co‐medication on dolutegravir glucuronidation in paediatric patients	9
Issue Information	9
	9
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma	9
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen	9
The impact of curricular revision on student performance in pharmacology assessments	9
Killing several birds with one stone: A multi‐indication population pharmacokinetic model and Bayesian estimator for enteric‐coated mycophenolate sodium	9
Pharmacogenomics in 2023: Big studies, big results, big implications, big responsibilities: Editorial	9
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men	9
Enlarged choroid plexus related to atrophy of hippocampal subfield volumes and glymphatic dysfunction in benzodiazepine use disorder	9
Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies	9
Implementability of opioid deprescribing interventions at transitions of care: A scoping review	9
Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels	9
Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review	9
A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation	9
Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19	9
Pharmacokinetics of long‐acting cabotegravir and rilpivirine in seminal plasma throughout the dosing interval	9
Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: A case report	9
Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)—Why do healthy volunteers participate in clinical trial	9
Population pharmacokinetics and Monte Carlo simulation of Cefepime in paediatric and Young adult bone marrow transplant patients	9
Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study	9
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen	9